Speciality: Oncology
Description:
Welcome to an insightful discussion on the critical topic of Cost Burden and Burden of Hospitalization for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Patients. Esteemed experts Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja delve into the multifaceted challenges faced by patients and healthcare systems. The conversation sheds light on the financial, emotional, and logistical strains of prolonged hospitalization, recurring treatments, and the socioeconomic disparities impacting access to advanced therapies. This session is a must-watch for healthcare professionals, policymakers, and caregivers seeking to understand the real-world implications of managing R/R ALL.
In the second segment, the panel explores actionable strategies to alleviate the burden on patients and families. Dr. Singh emphasizes the importance of cost-effective treatment protocols, while Dr. Dikshit highlights innovations in outpatient care models to reduce hospitalization frequency. Dr. Jain and Dr. Baveja further discuss the role of patient advocacy, insurance reforms, and government policies in bridging gaps in care. Their collective expertise provides a comprehensive roadmap to address systemic inefficiencies and improve the quality of life for R/R ALL patients.
Concluding on a hopeful note, the experts underscore the need for collaborative efforts between clinicians, researchers, and policymakers to drive sustainable change. The discussion not only raises awareness but also inspires actionable solutions to mitigate the economic and emotional toll of R/R ALL. Viewers are encouraged to watch the full video to gain deeper insights into this pressing issue and stay tuned for future discussions featuring these thought leaders in oncology and hematology.
See More Webinars @ Hidoc Webinars
1.
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
2.
Drugmaker Pulls Trodelvy's Bladder Cancer Approval
3.
Patients face high out-of-pocket costs after incident cancer diagnosis
4.
Childhood cancer survivors face new health problems later in life, study shows
5.
Mutation Clearance After Transplant Linked to Better Outcomes in Myelofibrosis
1.
The Statistical Horizon of Colorectal Cancer: From Global Trends to Precision Therapies and Colorectal Cancer 2025 Forecasts
2.
Understanding Hidrocystoma: Symptoms, Causes, and Treatment Options
3.
Understanding Histiocytosis: Symptoms, Causes, and Treatment Options
4.
Hepatocellular Carcinoma: Emerging Trends and Innovations in Diagnosis and Management
5.
Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
3.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
5.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation